Abstract:Background: The persistence of chemotherapy-resistant and dormant cancer cells remains a critical challenge in the treatment of lung cancer. Objectives: This review focuses on non-small cell lung cancer and small cell lung cancer, examining the complex mechanisms that drive treatment resistance. Methods: This review analyzed current studies on chemotherapy resistance in NSCLC and SCLC, focusing on tumor microenvironment, genetic mutations, cancer cell heterogeneity, and emerging therapies. Results: Conventional chemotherapy and targeted therapies, such as tyrosine kinase inhibitors, often fail due to factors including the tumor microenvironment, genetic mutations, and cancer cell heterogeneity. Dormant cancer cells, which can remain undetected in a quiescent state for extended periods, pose a significant risk of recurrence upon reactivation. These cells, along with intrinsic resistance mechanisms, greatly complicate treatment efforts. Understanding these pathways is crucial for the development of more effective therapies. Emerging strategies, including combination therapies that target multiple pathways, are under investigation to improve treatment outcomes. Innovative approaches, such as antibody–drug conjugates and targeted protein degradation, offer promising solutions by directly delivering cytotoxic agents to cancer cells or degrading proteins that are essential for cancer survival. The lung cancer organoid model shows substantial promise to advance both research and clinical applications in this field, enhancing the ability to study resistance mechanisms and develop personalized treatments. The integration of current research underscores the need for continuous innovation in treatment modalities. Conclusions: Personalized strategies that combine novel therapies with an in-depth understanding of tumor biology are essential to overcome the challenges posed by treatment-resistant and dormant cancer cells in lung cancer. A multifaceted approach has the potential to significantly improve patient outcomes.

Mechanisms of tumor cell resistance to the current targeted-therapy agents

Molecular mechanisms for tumor resistance to chemotherapy.

The Different Mechanisms of Cancer Drug Resistance: A Brief Review

Drug resistance in cancer: mechanisms and tackling strategies

Unveiling the mechanisms and challenges of cancer drug resistance

The molecular mechanisms of chemotherapeutic resistance in tumors (Review)

Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance

Drug resistance and combating drug resistance in cancer

Resistance Mechanisms of Tumour-Initiating Cells

Targeting Drug-Tolerant Cells: A Promising Strategy for Overcoming Acquired Drug Resistance in Cancer Cells.

A protracted war against cancer drug resistance

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons

Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure

Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment

Targeted Therapy: Resistance and Re-Sensitization

Multilevel Mechanisms of Cancer Drug Resistance

Breast Cancer: Molecular Mechanisms of Underlying Resistance and Therapeutic Approaches

Liposome-based approaches to overcome anticancer drug resistance

The Association Between Cancer and ABC Transporters